pertuzumab + gemcitabine + carboplatin

The combination **pertuzumab + gemcitabine + carboplatin** is an investigational multi-agent chemotherapy regimen primarily explored for the treatment of cancers such as metastatic breast cancer (especially HER2-positive subtype) and ovarian cancer. In this regimen, **pertuzumab** is a recombinant humanized monoclonal antibody targeting the dimerization domain of the human epidermal growth factor receptor 2 (HER2, also known as ERBB2), thereby inhibiting receptor heterodimerization and downstream signaling that drives tumor cell proliferation and survival. **Gemcitabine** is a nucleoside analog (antimetabolite) that inhibits DNA synthesis, leading to cell death in dividing cells. **Carboplatin** is a platinum-based alkylating agent that causes DNA crosslinking and inhibits DNA replication and transcription. The triplet aims to achieve synergistic antitumor effects, particularly in HER2-positive and platinum-sensitive malignancies. Clinical-phase studies have assessed this combination for efficacy, safety, and progression-free survival, notably in HER2-positive metastatic breast cancer after prior trastuzumab/pertuzumab therapy[5][7][8].